Capricor Therapeutics (CAPR) is a San Diego-based clinical-stage biotechnology company developing cell and exosome-based therapies, led by deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. In early Monday trading, the stock fell 6.72% to $8.89, down from the prior session's close of $9.53, having touched $8.57 shortly after the open. The direction is unambiguously lower. No company-issued news explained the drop; the move instead tracked a weekend FDA rejection for another developer, which refocused investors on the binary regulatory risk Capricor faces before Nov. 22.
The dominant catalyst came from outside the company. Summit Therapeutics (SMMT) disclosed on Sunday that the FDA had issued a complete response letter for its lung-cancer application, concluding that a delay in disease progression without a statistically significant overall survival benefit did not support approval. Summit shares fell about 10% in Monday's session.
That letter concerns an oncology endpoint and a different statutory playbook, and it carries no direct read-through to Capricor's functional-endpoint filing. Markets nonetheless treated it as a reminder that the agency has recently been strict on evidentiary thresholds — a sensitive point for a stock whose July advisory committee voted 9–3 against deramiocel's evidence in DMD-related cardiomyopathy, and whose shares collapsed roughly 64% in July when briefing documents questioned changes to the trial's statistical analysis plan. Capricor's request is now narrower, covering upper-limb impairment in patients older than nine, and rests on the HOPE-3 primary endpoint. Even so, positioning into a make-or-break decision day, traders reduced exposure rather than wait.
Monday's decline extends a retreat that began after the Nov. 11 session, when an upgrade to Buy and a cluster of reiterated Outperform ratings lifted the stock as high as $11.23 intraday. Oppenheimer kept a $54 target, Piper Sandler $25 and Cantor Fitzgerald $28, while Roth Capital raised its target to $10.50 but stayed Neutral, assigning only a 25% probability of approval by Nov. 22. That dispersion has since resolved in favor of caution: four consecutive down sessions have erased the entire post-upgrade gain, returning shares to the level they held before the rally.
Fundamentals added little support. Third-quarter results on Nov. 10 showed a GAAP loss of $0.73 per share, a net loss of roughly $42.7 million, operating expenses up sharply year over year, a workforce reduction of about 10%, and cash and securities of about $199 million with a stated runway of at least 12 months. With no product revenue, the equity remains a bet on a single regulatory event.
Biotechnology was modestly weaker as a session, with the sector benchmark down about 1.4% and the large-cap biotech proxy off roughly 0.7%. Capricor's decline outpaced both, confirming the move was stock- and story-specific rather than a broad risk-off wave. Turnover opened with a heavy burst and then settled near the stock's recent average daily pace, suggesting orderly de-risking rather than forced liquidation.
Technically, shares broke below the $8.85–$9.00 shelf that had contained the Nov. 10 low, then clawed back toward that zone, leaving the intraday breakdown only partly confirmed. The stock remains above a 20-day average near $7.70, and far above its 52-week low of $2.96, though it sits roughly 78% below the 52-week high of $40.37 and is down more than 65% year to date.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Capricor scores 20 out of 100.
The verified news was indirect: a peer company's regulatory rejection that shifts sentiment but reveals nothing new about deramiocel's data package, leaving catalyst strength modest relative to the company's size and binary profile. The move itself was unremarkable by Capricor's standards — 6.72% versus a typical daily swing of about 5.9% over the last 60 sessions, roughly 1.1 times the norm, with 20 of those sessions producing equal or larger moves. Weak news and a routine-sized move combine into a low score.
All attention converges on Nov. 22, the FDA's target action date for the deramiocel application. Beyond the approval decision itself, investors will focus on the breadth of any labeled indication, since a narrow population would limit commercial reach even in a positive outcome. Capricor has said its San Diego facility can support an initial launch covering roughly 250 patients annually, with a second-floor expansion targeted for validation in the first half of 2027.
Additional variables include the arbitration with NS Pharma over distribution rights, expected to begin hearings in mid-2027; the pace of payer and market-access discussions; and any further securities litigation developments tied to the earlier statistical analysis plan dispute. Analysts remain sharply divided, with targets spanning $7 to $54, and the company has no approved product or revenue. A delayed decision, a second complete response letter, or renewed cash-burn concerns are the principal downside risks, while approval would transform the equity's profile abruptly.
Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but the Trending AI Robots page narrows that universe to the strategies performing best under current market conditions. Bots differ widely by strategy logic, holding timeframe, performance metrics, and the symbols they trade, so the curated list changes as market regimes shift. For readers tracking volatile names like Capricor, it is a practical starting point for comparing live performance rather than relying on static backtests, and worth a review before the next catalyst lands.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CAPR saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 72 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on October 29, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.
CAPR moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The 10-day RSI Indicator for CAPR moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 56 cases where CAPR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.586). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology